Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -19.34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.85M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 141200 | Beta - | 52 Weeks Range 1.67 - 17.31 | Updated Date 06/19/2025 |
52 Weeks Range 1.67 - 17.31 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.64 |
Earnings Date
Report Date 2025-05-28 | When - | Estimate -0.62 | Actual -0.83 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.3% | Return on Equity (TTM) -68.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -111036961 | Price to Sales(TTM) 214.51 |
Enterprise Value -111036961 | Price to Sales(TTM) 214.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24363100 | Shares Floating 5916827 |
Shares Outstanding 24363100 | Shares Floating 5916827 | ||
Percent Insiders 19.99 | Percent Institutions 89.73 |
Analyst Ratings
Rating 4.67 | Target Price 15.4 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Artiva Biotherapeutics, Inc. Common Stock
Company Overview
History and Background
Artiva Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019. It focuses on developing allogeneic natural killer (NK) cell therapies for cancer. The company aims to enhance the accessibility, affordability, and efficacy of adoptive cell therapy.
Core Business Areas
- Allogeneic NK Cell Therapies: Developing and commercializing off-the-shelf, allogeneic NK cell therapies to treat various cancers.
Leadership and Structure
Peter Flynn serves as President and Chief Executive Officer. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- AB-101: An allogeneic NK cell therapy currently in clinical trials for the treatment of relapsed or refractory B-cell lymphomas. Market share data is not yet available due to its clinical stage. Competitors include companies developing CAR-T cell therapies and other NK cell therapies such as Nkarta and Fate Therapeutics.
- AB-201: An ADCC-enhanced NK cell therapy currently in preclinical development targeting HER2+ cancers. Market share data is not yet available due to its preclinical stage. Competitors include companies developing HER2-targeted therapies such as Roche/Genentech with Herceptin and Kadcyla.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in immunotherapy and personalized medicine. There's high demand for effective cancer treatments, creating opportunities for innovative therapies like NK cell therapies.
Positioning
Artiva is positioned as a key player in the allogeneic NK cell therapy space, aiming to overcome limitations of autologous cell therapies such as CAR-T. Its off-the-shelf approach could offer advantages in scalability and accessibility.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to be billions of dollars annually. Artiva is positioned to capture a significant share if its therapies demonstrate efficacy and safety in clinical trials.
Upturn SWOT Analysis
Strengths
- Allogeneic NK cell platform
- Potential for off-the-shelf availability
- Experienced management team
- Strong scientific foundation
Weaknesses
- Clinical stage company with no approved products
- Dependence on clinical trial success
- High cash burn rate
- Competition from established players
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new cancer targets
- Positive clinical trial results
- Advancements in NK cell engineering
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapies
- Financing risks
Competitors and Market Share
Key Competitors
- NKarta, Inc.(NKTX)
- Fate Therapeutics(FATE)
- Century Therapeutics(ISTC)
Competitive Landscape
Artiva competes with other companies developing cell therapies for cancer. Its advantages include its allogeneic NK cell platform and its focus on enhancing NK cell activity. Disadvantages include its clinical stage and dependence on clinical trial success. All of the competitors are clinical stage companies so market share data is not available
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its clinical pipeline and the expansion of its scientific team.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections would be available from investment banks covering the company.
Recent Initiatives: Recent initiatives include the advancement of AB-101 in clinical trials and the development of AB-201 in preclinical studies.
Summary
Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic NK cell therapies for cancer. The company's key strength lies in its allogeneic NK cell platform, offering the potential for off-the-shelf availability. It currently faces challenges typical of a clinical-stage company, including dependence on clinical trial outcomes and high cash burn. Successful clinical trials and potential partnerships represent opportunities for growth, while clinical trial failures and competition from established players pose threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Artiva Biotherapeutics, Inc. SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://www.artivabio.com |
Full time employees 96 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.